Nevertheless, we observed that IHC staining performed with the commercial Bek antibody (Table 7) could highlight only a partial decrease of FGFR2 IHC score in thyroid cancer samples (Fig. 6, panels C, C′), with respect to normal thyroid tissue (Fig. 6, panels A, A′) (145.6 ± 34.8, score 2, vs 220.6 ± 6.3, score 3), thus indicating that Bek antibody was not efficient to detect significant variations of FGFR2 expression in thyroid carcinoma due to poor sensitivity and high background. Here, FGFR2 is linked to thyroid cancer.